Bavarian Nordic to acquire Vivotif and Vaxchora travel vaccines from Emergent BioSolutions

Bavarian Nordic to acquire Vivotif and Vaxchora travel vaccines from Emergent BioSolutions

Bavarian Nordic A/S will acquire two oral vaccines from Emergent BioSolutions for a total consideration of up to $380 million, to strengthen its position in the travel vaccines space. The acquisition is expected to help Bavarian Nordic expand its US commercial sales, marketing, and distribution network, as well as increased scale in additional European markets. […]

Emergent BioSolutions begins phase 3 trial of CHIKV VLP vaccine candidate

Emergent BioSolutions begins phase 3 trial of CHIKV VLP vaccine candidate

Emergent BioSolutions said that it has dosed the first participant in a phase 3 clinical trial of CHIKV VLP — the company’s single-dose chikungunya vaccine candidate. The American biopharma company will test the safety and immunogenicity of the investigational chikungunya virus (CHIKV) virus-like particle (VLP) vaccine. According to Emergent BioSolutions, CHIKV VLP is the only […]